# US 2019/0336785 A1 · Non-invasive energy upconversion methods and systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0336785 A1
- Document ID: US20190336785A1
- Status: Published application
- Kind: A1
- Application number: 16/511,536
- Filed: 2019-07-15
- Published: 2019-11-07
- Earliest claimed: 2009-04-21
- Assignees: Immunolight, LLC; Duke University
- Applicants: Immunolight, LLC; Duke University
- Inventors: Tuan VO-DINH; Jonathan P. Scaffidi; Venkata Gopal Reddy Chada; Benoit Lauly; Yan Zhang; Molly K. Gregas; Ian Nicholas Stanton; Joshua T. Stecher; Michael J. Therien; Frederic A. Bourke, JR.; Harold Walder; Zak Fathi; Jennifer A. Ayres; Zhenyuan Zhang; Joseph H. Simmons; Stephen John Norton
- Web page: https://patentgrep.com/patent/US20190336785A1

## CPC

- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61B 5/0059: {using light, e.g. diagnosis by transillumination, diascopy, fluorescence (photoacoustic A61B5/0093; optical measurement of heart rate A61B5/02416; optical measurement of blood flow A61B5/0261; optical measurement of analytes A61B5/1455)}
- A61B 5/0071: {by measuring fluorescence emission}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61B 6/481: {involving the use of contrast agents}
- A61K 41/0042: {Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion}
- A61K 41/0052: {Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy}
- A61K 41/0061: {5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA}
- A61K 49/0039: {Coumarin dyes}
- A61L 2/10: Ultraviolet [UV] radiation
- A61M 5/007: {for contrast media}
- A61N 1/406: {using implantable thermoseeds or injected particles for localized hyperthermia (preparations of seeds and particles A61K41/0052)}
- A61N 5/02: using microwaves
- A61N 5/0601: {Apparatus for use inside the body}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/08: of the prostate
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61L 2/08: Radiation
- A61L 2103/05: Living organisms or biological materials
- A61L 2103/09: Blood or products thereof
- A61N 5/0618: {Psychological treatment}
- A61N 5/0622: {Optical stimulation for exciting neural tissue}
- A61N 5/0624: {for eliminating microbes, germs, bacteria on or in the body}
- A61N 5/067: using laser light
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61N 2005/063: {comprising light transmitting means, e.g. optical fibres}
- A61N 2005/0656: {Chemical light sources}
- A61N 2005/0659: {infrared}
- A61N 2005/0662: {Visible light}
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

## Claims

### Claim 1

(canceled)

### Claim at position 2

2: A method for modifying a target structure which mediates or is associated with a biological activity, comprising:
placing in a vicinity of a target structure in a subject in need of treatment an agent receptive to microwave radiation or radiofrequency radiation; and
applying as an initiation energy said microwave radiation or radiofrequency radiation by which the agent directly or indirectly generates emitted light in the infrared, visible, or ultraviolet range, wherein the emitted light contacts the target structure and induces a predetermined change in said target structure in situ,
wherein said predetermined change modifies the target structure and modulates the biological activity of the target structure.

### Claim at position 3 (depends on 2)

3: The method of claim 2, wherein placing an agent comprises placing a nanoparticle including a metallic structure in relation to the nanoparticle.

### Claim at position 4 (depends on 3)

4: The method of claim 3, wherein placing the nanoparticle comprises placing a nanoparticle having a dielectric core.

### Claim at position 5 (depends on 4)

5: The method of claim 4, wherein placing the nanoparticle comprises at least one of:
placing a nanoparticle having a metallic shell including at least one of a spherical shell, an oblate shell, a crescent shell, a multilayer shell, or an array of metal nanoislands on the surface of the core nanoparticle in the vicinity of the target structure;
placing a nanoparticle having an array of metal nanoislands on the surface of the core nanoparticle in the vicinity of the target structure; or
placing a nanoparticle having an array of nanoislands on the surface of the core nanoparticle in the vicinity of the target structure.

### Claim at position 6 (depends on 4)

6: The method of claim 4, wherein the nanoparticle comprises a metallic structure comprising at least one of element selected from the group consisting of Au, Ag, Cu, Ni, Pt, Pd, Co, Ru, Rh, Al, Ga, and a combination thereof.

### Claim at position 7 (depends on 4)

7: The method of claim 4, wherein the nanoparticle comprises a core comprising least one compound selected from the group consisting of Y2O3, Y2O2S, NaYF4, YAG, YAP, Nd2O3, LaF3, LaCl3, La2O3, TiO2, LuPO4, YVO4, YbF3, YF3, Na-doped YbF3, SiO2 and alloys or layers thereof.

### Claim at position 8 (depends on 4)

8: The method of claim 4, wherein the nanoparticle comprises a dopant comprising at least one of element selected from the group consisting of Er, Eu, Yb, Tm, Nd, Tb, Ce, Y, U, Pr, La, Gd, other rare-earth species and a combination thereof.

### Claim at position 9 (depends on 2)

9: The method of claim 2, wherein placing an agent comprises placing at least one of a phosphorescent molecule, a fluorescent molecule, or a luminescent inorganic molecule, each displaying emission upon exposure to said microwave radiation or radiofrequency radiation.

### Claim at position 10 (depends on 2)

10: The method of claim 2, wherein placing an agent comprises placing at least one of a chemiluminescent molecule, displaying emission upon exposure to said microwave radiation or radiofrequency radiation.
